Amplexd Therapeutics is focused on developing innovative, non-invasive solutions for the treatment of cervical intraepithelial neoplasia (CIN), particularly those induced by human papillomavirus (HPV). Their approach combines advanced pharmacology with medical device design to create effective treatments that prioritize patient safety and accessibility. Among their solutions in development are self-administered intravaginal suppositories aimed at treating low-grade dysplasia (ASCUS and CIN1) and a Cold Light Photodynamic Therapy (PDT) system designed for the rapid treatment of higher-grade dysplasia (CIN2 and CIN3). This holistic approach to product development emphasizes individualized patient care and aims to address the public health crisis associated with HPV and cervical cancer.

The team at Amplexd Therapeutics is composed of experienced professionals from various fields, including pharmacology, medical device innovation, and product development. Co-founder Alia Rahman, a patient-scientist and advocate for women's health, leads the mission to create non-invasive treatments that enhance patient experience and access. Dr. Reid von Borstel, another co-founder, brings a wealth of expertise in drug discovery and medical device development, having previously invented FDA-approved drugs and medical devices. Valent Turkovic, the Medical Device Program Manager, contributes his extensive background in innovation and product development, particularly in creating solutions that can revolutionize the treatment landscape for cervical dysplasia and early cervical cancer. Together, the team is committed to advancing accessible healthcare solutions for women facing these challenges.

United States

Amplexd is a patient-scientist led company, comprising pharmaceutical industry veterans and senior product developers blending the best of cutting-edge technology and patient-centric design to develop accessible, non-invasive treatments for HPV-induced cervical dysplasia.

Amplexd Therapeutics

Company Details